Germany’s CureVac starts human trials for COVID-19 vaccine

German biotech firm CureVac has won permission to start human trials of a promising coronavirus vaccine, regulators announce, as the global race to stop the pandemic gathers pace.

The Paul Ehrlich Institute (PEI), the German body responsible for assessing clinical trials and approving vaccines, calls the approval “an important milestone.”

In a statement, it said it had given CureVac the green light based on “a careful assessment of the risk/benefit profile of the vaccine candidate.”

Globally, there are now 11 coronavirus vaccines being tested on humans, according to the World Health Organization.

AFP

Most Popular
If you’d like to comment, join
The Times of Israel Community.
Join The Times of Israel Community
Commenting is available for paying members of The Times of Israel Community only. Please join our Community to comment and enjoy other Community benefits.
Please use the following structure: example@domain.com
Confirm Mail
Thank you! Now check your email
You are now a member of The Times of Israel Community! We sent you an email with a login link to . Once you're set up, you can start enjoying Community benefits and commenting.